Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prepn process of polysaccharide vitreous particle carrying active vaccine or antibody

A vitreous body and vaccine technology, applied in the field of biomedicine, can solve the problems of unknown changes in the properties of vaccines, achieve the effects of maintaining activity and therapeutic effect, improving release kinetics, and increasing release rate

Inactive Publication Date: 2009-11-04
SHANGHAI JIAO TONG UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this technology is aimed at non-protein subunit vaccines, but uses protein as a carrier, which makes it difficult to avoid the immunogenicity of the heterologous protein itself, and it is through chemical modification. The same chemical modification leads to changes in the properties of the vaccine itself. Know

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] 1. Preparation of vaccine or antibody-polysaccharide vitreous body by low temperature water phase-water phase emulsion method

[0037] ① Preparation of vaccine vaccine or antibody, PEG and polysaccharide aqueous solution

[0038] Prepare 10% PEG and 10% polysaccharide aqueous solution with ultrapure water, accurately weigh 10 grams of PEG and 10 grams of polysaccharide water, add 90 grams of water to a 100 ml beaker, and then place the two beakers on a heated magnetic Stir for 30 minutes, wait for the PEG and 10% polysaccharide to dissolve completely, take it out and cool it for later use. Use an electronic balance to accurately weigh 800 mg of vaccine or antibody and dissolve it in 7.2 ml of water for use.

[0039] Prepare vaccine or antibody, PEG and polysaccharide aqueous phase-aqueous phase emulsion

[0040] Under the condition of 0°C-4°C, the polysaccharide, vaccine or antibody and PEG aqueous solution of 1. were mixed according to the volume ratio of 1:1:5, 1:1:...

Embodiment 2

[0051] 1. Preparation of vaccine or antibody-polysaccharide vitreous by low temperature induced phase separation

[0052] ① Preparation of vaccine or antibody, PEG and polysaccharide aqueous solution

[0053] Prepare 5% PEG and 5% polysaccharide aqueous solution with ultrapure water, accurately weigh 5 grams of PEG and 5 grams of polysaccharide water, add 95 grams of water to a 100 ml beaker, and then place the two beakers on a heated magnetic Stir for 30 minutes, wait until the PEG and 5% polysaccharide are completely dissolved, take it out and cool it for later use. Accurately weigh 400 milligrams of protein with an electronic balance and dissolve it in 3.6 milliliters of water for use.

[0054] ② Vaccine or antibody, PEG and polysaccharide homogeneous co-solution

[0055] Vortex the polysaccharide, vaccine or antibody and PEG aqueous solution in ① according to the volume ratio of 1:1:5, 1:1:10, 1:1:20, 1:1:40 in the vial and mix thoroughly for 30s-60s, Form a homogeneous...

Embodiment 3

[0066] Stable Aqueous-Aqueous Emulsion Method

[0067] Most of the particle diameters of the obtained vaccine- or antibody-loaded polysaccharide dispersed-phase vitreous bodies are 300nm-5μm, and the obtained vitreous bodies are smooth and round with uniform particle size distribution. The structure of the vaccine or antibody can be well protected, and the inactivation during the preparation of the dosage form can be avoided.

[0068] Weigh 100 mg of polylactic acid-polyglycolic acid (PLGA), and dissolve it fully in 1 ml of acetonitrile under the action of a vortex mixer, then weigh 10 mg of vaccine or antibody polysaccharide vitreous body into the acetonitrile solution, and stir under magnetic force fully dispersed. Add 200ml of cottonseed oil surfactant span80 to a certain amount of external oil phase solution, and fully mix with an electric stirrer at 200rpm. Add the acetonitrile solution dispersed with vaccine or antibody polysaccharide vitreous body dropwise into the st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to biotechnology, and is especially preparation process of vitreous polysaccharide particle carrying active vaccine or antibody. The preparation process includes the following steps: 1. adding vaccine or antibody into polysaccharide solution; 2. mixing at temperature over freezing point; 3. freeze drying the mixture solution or emulsion to obtain powder; and 4. washing the powder with organic solvent capable of dissolving polyethylene glycol to eliminate polyethylene glycol and obtain polysaccharide particle carrying active vaccine or antibody. Thus prepared vitreous polysaccharide particle carrying active vaccine or antibody has smooth round surface and adjustable size of 0.1-10 micron, long term maintained activity and treating effect.

Description

technical field [0001] The invention relates to a preparation method in the technical field of biomedicine. In particular, a method for preparing polysaccharide vitreous particles loaded with active vaccines or antibodies. Background technique [0002] Immunotherapy plays an important role in the prevention and treatment of infectious diseases and tumors. The means of immunotherapy is nothing more than the use of various antigens and antibodies to the human body. Antibodies, whether monoclonal or polyclonal, are protein macromolecules, and the principles of antibodies are quite diverse, including cells, viruses, proteins, polypeptides, and genetic material. [0003] In the past 10 years, slow-release microspheres based on degradable and biocompatible polymers have been successfully applied in small molecule chemical drugs and peptide drugs. or multi-pulse) release, resulting in sustained antibody responses and other immune responses have also been reported. The work of i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/16A61K47/34A61K47/38A61K39/395A61K39/12A61K47/10
CPCY02A50/30
Inventor 金拓袁伟恩吴飞
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com